Regulatory Post Marketing Surveillance Study on Nexavar®
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
Carcinoma, Hepatocellular|Carcinoma, Renal Cell
DRUG: Sorafenib (Nexavar, BAY43-9006)
Adverse events collection, From start of treatment to 4 weeks after discontinuation of treatment
Duration of treatment, dosage and indication, Whole treatment period|Tumor status, Whole treatment period|Performance status, Whole treatment period
The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®.

1. Unknown adverse events (in particular, serious adverse events)
2. Identification of adverse events occurred in the real practice.
3. Factors that are considered to affect on safety.
4. Factors that are considered to affect on effectiveness